Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Personalis, Inc. (NASDAQ:PSNL) has received a consensus rating of "Buy" from five research firms, with an average price target of $7.42 for the stock.
• Institutional investors own 61.91% of Personalis, with significant increases in holdings by firms such as Lightspeed Management and Aberdeen Group.
• The company's latest earnings report showed a revenue of $17.20 million, which is below the estimated $20.12 million, and it reported an EPS of ($0.23), beating estimates.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) has been assigned a consensus rating of "Buy" from the five ratings firms that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have covered the stock in the last year is $7.4167.

Several equities analysts have recently commented on the company. BTIG Research set a $6.00 price target on Personalis in a research note on Wednesday, August 6th. HC Wainwright decreased their target price on Personalis from $9.00 to $8.50 and set a "buy" rating for the company in a report on Wednesday, August 6th. Guggenheim initiated coverage on Personalis in a research report on Thursday, May 15th. They set a "buy" rating and a $6.00 price target for the company. Finally, Wall Street Zen cut Personalis from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th.

Hedge Funds Weigh In On Personalis

Several hedge funds have recently bought and sold shares of PSNL. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Personalis in the 4th quarter valued at approximately $28,000. Legal & General Group Plc purchased a new stake in Personalis during the second quarter valued at about $30,000. JPMorgan Chase & Co. lifted its stake in shares of Personalis by 2,827.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock worth $34,000 after acquiring an additional 5,654 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in shares of Personalis during the second quarter valued at approximately $34,000. Finally, BNP Paribas Financial Markets lifted its position in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock valued at $42,000 after acquiring an additional 5,177 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.

Personalis Price Performance

NASDAQ:PSNL remained flat at $4.78 during midday trading on Friday. The company had a trading volume of 535,711 shares, compared to its average volume of 1,074,419. The firm has a 50-day moving average price of $5.81 and a two-hundred day moving average price of $4.85. Personalis has a one year low of $2.83 and a one year high of $7.79. The stock has a market cap of $423.89 million, a price-to-earnings ratio of -3.73 and a beta of 1.86.

Personalis (NASDAQ:PSNL - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%.The business had revenue of $17.20 million for the quarter, compared to analyst estimates of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, analysts anticipate that Personalis will post -1.4 earnings per share for the current fiscal year.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.